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Abstract: 
 
Objective: The heterogeneity of soft tissue sarcoma (STS) represents a major challenge for the 
development of effective therapeutics. Comprised of over 50 different histology subtypes of 
various etiologies, STS subsets are further characterized as either karyotypically simple or 
complex. Due to the number of genetic anomalies associated with genetically complex STS, 
development of therapies demonstrating potency against this STS cluster is especially 
challenging and yet greatly needed. Verticillin A is a small molecule natural product with 
demonstrated anticancer activity; however, the efficacy of this agent has never been evaluated in 
STS. Therefore, the goal of this study was to explore verticillin A as a potential STS therapeutic. 
 
Methods: We performed survival (MTS) and clonogenic analyses to measure the impact of this 
agent on the viability and colony formation capability of karyotypically complex STS cell lines: 
malignant peripheral nerve sheath tumor (MPNST) and leiomyosarcoma (LMS). The in vitro 
effects of verticillin A on apoptosis were investigated through annexin V/PI flow cytometry 
analysis and by measuring fluorescently-labeled cleaved caspase 3/7 activity. The impact on cell 
cycle progression was assessed via cytometric measurement of propidium iodide intercalation. In 
vivo studies were performed using MPNST xenograft models. Tumors were processed and 
analyzed using immunohistochemistry (IHC) for verticillin A effects on growth (Ki67) and 
apoptosis (cleaved caspase 3). 
 
Results: Treatment with verticillin A resulted in decreased STS growth and an increase in 
apoptotic levels after 24 h. 100 nM verticillin A induced significant cellular growth abrogation 
after 24 h (96.7, 88.7, 72.7, 57, and 39.7% reduction in LMS1, S462, ST88, SKLMS1, and 
MPNST724, respectively). We observed no arrest in cell cycle, elevated annexin, and a nearly 
two-fold increase in cleaved caspase 3/7 activity in all MPNST and LMS cell lines. Control 
normal human Schwann (HSC) and aortic smooth muscle (HASMC) cells displayed higher 
tolerance to verticillin A treatment compared to sarcoma cell lines, although toxicity was seen in 
HSC at the highest treatment dose. In vivo studies mirrored the in vitro results: by day 11, tumor 
size was significantly reduced in MPNST724 xenograft models with treatment of 0.25 and 0.5 
mg/kg verticillin A. Additionally, IHC assessment of tumors demonstrated increased cleaved 
caspase 3 and decreased proliferation (Ki67) following treatment with verticillin A. 
 
Conclusion: Advancement in the treatment of karyotypically complex STS is confounded by the 
high level of genetic abnormalities found in these diseases. Consequently, the identification and 
investigation of novel therapies is greatly needed. Our data suggest that verticillin A selectively 
inhibits MPNST and LMS growth via induction of apoptosis while exhibiting minimal to 
moderate effects on normal cells, pointing to verticillin A as a potential treatment for MPNST 
and LMS, after additional preclinical validation. 
 
Keywords: Verticillin A | Epipolythiodioxopiperazine alkaloid | Malignant peripheral nerve 
sheath tumor | MPNST | Leiomyosarcoma | LMS | Apoptosis | Soft tissue sarcoma | STS 
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Abstract
Objective: The heterogeneity of soft tissue sarcoma (STS) represents a major challenge for the development of
effective therapeutics. Comprised of over 50 different histology subtypes of various etiologies, STS subsets are
further characterized as either karyotypically simple or complex. Due to the number of genetic anomalies associated
with genetically complex STS, development of therapies demonstrating potency against this STS cluster is
especially challenging and yet greatly needed. Verticillin A is a small molecule natural product with demonstrated
anticancer activity; however, the efficacy of this agent has never been evaluated in STS. Therefore, the goal of this
study was to explore verticillin A as a potential STS therapeutic.
Methods: We performed survival (MTS) and clonogenic analyses to measure the impact of this agent on the
viability and colony formation capability of karyotypically complex STS cell lines: malignant peripheral nerve sheath
tumor (MPNST) and leiomyosarcoma (LMS). The in vitro effects of verticillin A on apoptosis were investigated
through annexin V/PI flow cytometry analysis and by measuring fluorescently-labeled cleaved caspase 3/7 activity.
The impact on cell cycle progression was assessed via cytometric measurement of propidium iodide intercalation. In
vivo studies were performed using MPNST xenograft models. Tumors were processed and analyzed using
immunohistochemistry (IHC) for verticillin A effects on growth (Ki67) and apoptosis (cleaved caspase 3).
Results: Treatment with verticillin A resulted in decreased STS growth and an increase in apoptotic levels after
24 h. 100 nM verticillin A induced significant cellular growth abrogation after 24 h (96.7, 88.7, 72.7, 57, and 39.7%
reduction in LMS1, S462, ST88, SKLMS1, and MPNST724, respectively). We observed no arrest in cell cycle,
elevated annexin, and a nearly two-fold increase in cleaved caspase 3/7 activity in all MPNST and LMS cell lines.
Control normal human Schwann (HSC) and aortic smooth muscle (HASMC) cells displayed higher tolerance to
verticillin A treatment compared to sarcoma cell lines, although toxicity was seen in HSC at the highest treatment
dose. In vivo studies mirrored the in vitro results: by day 11, tumor size was significantly reduced in MPNST724
xenograft models with treatment of 0.25 and 0.5 mg/kg verticillin A. Additionally, IHC assessment of tumors
demonstrated increased cleaved caspase 3 and decreased proliferation (Ki67) following treatment with verticillin A.
Conclusion: Advancement in the treatment of karyotypically complex STS is confounded by the high level of
genetic abnormalities found in these diseases. Consequently, the identification and investigation of novel therapies
is greatly needed. Our data suggest that verticillin A selectively inhibits MPNST and LMS growth via induction of
apoptosis while exhibiting minimal to moderate effects on normal cells, pointing to verticillin A as a potential
treatment for MPNST and LMS, after additional preclinical validation.
Keywords: Verticillin A; Epipolythiodioxopiperazine alkaloid;
Malignant peripheral nerve sheath tumor; MPNST; Leiomyosarcoma;
LMS; Apoptosis; Soft tissue sarcoma; STS
Introduction
STS is a rare cancer of mesenchymal origin accounting for less than
1% of adult solid malignancies. This tumor cluster encompases over 50
subtypes, ranging from the highly metastatic (e.g., Ewing sarcoma) to
those unable to metastasize from the primary site of development (e.g.,
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desmoid tumor) [1]. These STS subsets are further characterized as
genetically simple or complex cancers based on the presence or
absence of fusion proteins as well as chromosome abnormalities [2,3].
Overall, STS patients experience high risks of local recurrence, distant
metastasis, and unacceptably low disease-free survival [4-6], especially
in the case of high grade STS. This reality points to the lack of effective
systemic treatment options for patients. Conventional STS treatment
includes chemotherapy and radiation therapy, as well as total surgical
excision, all of which can have serious quality of life consequences [4].
Drug combinations, such as doxorubicin and ifosfamide, are
commonly used in the treatment of these malignancies, albeit with
modest efficacy:toxicity ratios [4-8].
Multiple chromosomal abnormalities including regional mutation,
deletion, and amplification events render the effective treatment of
complex karyotype STS extremely difficult [2,9]; the utilization of
multiple aberrantly regulated pathways by these genetically complex
malignancies not only complicates the development of targeted
therapies but also increases the likelihood of therapeutic resistance.
Identification of systemic therapy exhibiting selective potency with
minimal patient toxicity is therefore critical.
Verticillin A is a small molecule member of a large and diverse
family of epipolythiodioxopiperazine (ETP) alkaloids [10]. Identified
as a fungal toxin released in response to pathogen infection, the
anticancer capacity of verticillin A has been observed in metastatic
colon carcinoma [11,12]. Although verticillin A displayed high efficacy
as a single agent in this disease, combining verticillin A with TRAIL in
a treatment approach resulted in both the potentiation of TRAIL as
well as the reduction in the concentration of verticillin A required for
demonstrable effect, hence our interest in evaluating the utility of this
compound in STS.
Materials and Methods
Reagents and drugs
Verticillin A was purified from culture MSX59553 from the
Mycosynthetix fungal library, as described in detail previously [10]; the
sample was re-isolated from MSX59553 and was >95% pure as
measured by UPLC. Aliquots of verticillin A were reconstituted in
dimethyl sulfoxide (DMSO; Fisher Bioreagents, Pittsburg, PA, USA)
for in vitro studies or cremophor EL (Sigma-Aldrich, St. Louis, MO,
USA) for in vivo investigations, and stored at -20º C. Antibodies
(cleaved caspase 3, #9661S and Ki67, #VP-K451) used for
immunohistochemistry (IHC) assessment were purchased from Cell
Signaling (Danvers, MA, USA) and Vector Laboratories (Burlingame,
CA, USA), respectively, and used at a dilution of 1:1000. Propidium
iodide (PI; #P4864-10ML) was obtained from Sigma-Aldrich (St. Louis,
MO, USA).
Cell culture and cell lines
Human NF1-associated MPNST cell lines, ST88 and S462, and
sporadic MPNST cell line, MPNST724, have been previously described
[13]. MPNST724 and ST88 were attained from Dr. Jonathan Fletcher
(Brigham and Women’s Hospital, Boston, MA, USA), and S462 was
acquired from Dr. Lan Kluwe (University Hospital Eppendorf,
Hamburg, Germany). LMS cell lines SKLMS1 and LMS1 were acquired
from ATCC (Manassas, VA, USA) and Dr. Dominique Broccoli
(Mercer University, Savannah, GA, USA), respectively. Cells were
cultured in complete DMEM (DMEM with sodium pyruvate, L-
glutamine, high glucose, 10% FBS and 100 µg/mL Normacin) and
maintained at 37º C at 5% CO2 for the duration of the experiments.
Human Schwann (HSC) and aortic smooth muscle (HASMC) cells
(ScienCell, Carlsbad, CA, USA) were cultured in the appropriate
media as described by supplier protocol and used as controls for in
vitro assays. Primocin, used to supplement normal cell media, and
Normacin, added to sarcoma cell media, were purchased from
Invitrogen (Carlsbad, CA, USA). DMEM (#11995-065) was purchased
from Thermo-Fisher (Grand Island, NY).
Cell viability analysis
MTS analysis was performed using CellTiter96 Aqueous Non-
Radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA)
as specified by the manufacturer. Cells were seeded at a density of
5,000 cells per well, and allowed to adhere overnight. Cellular viability
was assessed 24 h after treatment with DMSO (control), or 10, 50, or
100 nM verticillin A, and absorbance was measured at 490 nm
wavelength.
Clonogenic analysis
Cells were seeded at 800 cells per well in a 6-well plate (9.5 cm2) and
allowed to attach overnight prior to treatment with DMSO or varying
concentrations of verticillin A. Cells were treated for 24 h, then
changed to recovery media and allowed to continue to grow for 10
days. Colonies were stained using 0.5% crystal violet solution in
methanol for 30 min. Staining solution was removed, wells were
washed with deionized H2O, and stained colonies were imaged and
counted.
Apoptosis analysis
Apoptosis was measured by quantifying cleaved-caspase 3 and
cleaved-caspase 7 activity using Cell Event Caspase 3/7 Green
Detection Reagent (Life Technologies, Carlsbad, CA, USA) in the
Incucyte Zoom system (Essen BioScience, Ann Arbor, MI, USA). Cells
were plated at a density of 4,200 cells per well and allowed to adhere.
The cells were then treated with DMSO or 10, 50, or 100 nM verticillin
A for 24 h, and caspase activity was monitored using fluorescent Cell
Event Caspase 3/7 Reagent (5 μM final concentration). Endpoint
analysis was performed in each well using a final concentration of 10
μM Vybrant DyeCycle Green Stain (Life Technologies, Carlsbad, CA,
USA) in complete DMEM. Apoptosis was confirmed using the
Apoptosis Detection Kit (BD Pharmagen, San Diego, CA, USA) in
complete DMEM. Per supplier instructions, 1 × 106 cells/mL were
stained with 5 µL Annexin V-FITC and 5 μL propidium iodide
following 24 h treatment with DMSO or 10, 50, or 100 nM verticillin A
and analyzed via FACS analysis (LSR II, BD Pharmagen, San Diego,
CA, USA).
Cell cycle analysis
Cells were synchronized by 16 h starvation prior to treatment with
DMSO, 10, 50, or 100 nM of verticillin A for 24 h. Attached and
floating cells were collected following treatment and centrifuged for 5
min at 2500 RPM. Supernatant was removed and cells were washed
twice with cold PBS. Cells were centrifuged (2500 RPM/5 min) and
resuspended in 70% ethanol and fixed overnight at -20º C. Cells were
then centrifuged at (2500 RPM/5 min), and ethanol was removed.
Subsequently, cells were resuspended in 400 μL PI stain (0.05 mg/mL/
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1 mg/mL sodium citrate/ 50 μL Triton-X-100/ 50 μL RNase A, brought
to 50 mL with PBS) and analyzed via LSR II FACS analysis.
In vivo animal models
Six week old female SCID mice (Taconic Biosciences, Hudson, NY,
USA; model #CB17SC) were injected subcutaneously with 1 × 106
MPNST724 cells into the flank. Once tumors reached 0.5 cm, mice
were allocated into three arms (10 mice per arm) and treatment via
intraperitoneal injections was initiated: Vehicle (5% ethanol/15%
cremophor EL/80% PBS), verticillin A (0.25 mg/kg every other day), or
verticillin A (0.5 mg/kg every other day). Mice were weighed and
tumors were measured twice weekly. Mice were euthanized once
tumors in the control group grew to ~1.5 cm. Final tumor volumes and
weights were measured, and tumors were processed for IHC analysis.
Immunohistochemistry and H&E analyses
Ki67 (Vector Laboratories) and cleaved caspase 3 (Cell Signaling)
antibodies were used to identify the effect of verticillin A on
proliferation and apoptosis, respectively. IHC staining was conducted
at Nationwide Children’s Hospital (Columbus, OH) and analysis was
performed at the Polaris Innovation Center (The Ohio State University,
Columbus, OH, USA). IHC samples and analyses were verified by
pathologist, O. Hans Iwenofu, M.D. (The Ohio State University,
Department of Pathology, Columbus, OH, USA).
Statistics
In vitro analyses were performed in triplicate. Mean ± SEM
(standard error mean) calculations and statistical analyses were
performed for all cell-based assays, and EC50 values were computed
using GraphPad Prism version 6.00 (for Windows, GraphPad Software,
La Jolla California USA, www.graphpad.com). All Student t tests
performed were unpaired and two-sided. The average tumor volume
(mm3) and weight (kg) for each study arm was measured and
recorded. Mean ± SEM was calculated for each treatment group, and
end-point analyses determined using unpaired two-sided t test was
utilized to determine variances. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
Results
Verticillin A affects STS cellular viability and colony
formation capability
To assess the effect of verticillin A on STS, genetically complex
MPNST and LMS cell lines were treated with increasing doses of
verticillin A (Figure 1A). Primary cultured human Schwann (HSC)
and smooth muscle (HASMC) cells were used to evaluate the effects of
this compound on normal control cells. Verticillin A showed no effect
on HASMC at 100 nM and a displayed potency in HSC (EC50=64.94
nM) (Table 1) (Figure 1B). Following 24 h of treatment, verticillin A
demonstrated a marked inhibitory effect on S462, ST88, and LMS1 at
10 nM while MPNST724 and SKLMS1 exhibited tolerance at this dose
(Figure 1C). All STS cell lines displayed a significant decrease in
viability with 100 nM verticillin A. The effects elicited in these complex
karyotype STS cell lines, as compared to normal cells, suggest the
possible selective inhibitory capacity of these agents.
Verticillin A also inhibited colony formation capacity in STS cells;
with all doses of verticillin A, all MPNST and LMS cell lines were
unable to form colonies (Figure 1D). We next investigated whether the
response of these STS cells was due to a compound-mediated cell cycle
arrest. No substantial arrest in cell cycle progression was demonstrable
in MPNST or LMS (Figure 1E), indicating that anticancer effect of
verticillin A is independent of cycle arrest (Figure 1).
Cell Line EC50 (Nm)
HASMC 250.7
HSC 64.94
MPNST724 124.6
S462 26.03
SKLMS1 74.56
LMS1 10.69
Table 1: EC50 values of normal and STS cell lines were determined via
MTS assessment after 24 h treatment with verticillin A.
Verticillin A induces apoptosis in MPNST and LMS
Published works indicate that verticillin A impedes tumor growth
via stimulation of apoptotic machinery [11]. Therefore, induction of
apoptosis in STS was initially explored as a potential mechanism of
action. Cleaved caspase 3 and 7 activities, markers of apoptosis, were
measured using fluorescent Cell Event Caspase 3/7 Reagent. When
activated, these caspases recognize the caspase-3/7 recognition motif
(DEVD) on the Caspase 3/7 Reagent and cleave the substrate, thereby
releasing the fluorescent DNA intercalating dye. The dye then binds
DNA and produces a measurable signal. All STS cell lines displayed
increased caspase activity whereas the effects on HSC and HASMC (1.1
and 1.2 fold change, respectively) were modest (Figure 2A). Annexin
V/PI staining further supported this finding. All STS cell lines, but not
normal control cells, exhibited significantly increased apoptosis upon
verticillin A treatment (LMS1, 73.4 ± 12.7%; MPNST724, 34 ± 4.3%;
SKLMS1, 29.4 ± 2.3%; S462, 25.9 ± 3.75%) (Figure 2B). Taken together,
these data suggest that verticillin A inhibits STS growth via induction
of apoptosis (Figure 2).
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Figure 1: STS treated with verticllin A demonstrate decreased cell viability in vitro. (A) Molecular structure of verticillin A. (B) MTS analysis
of normal cells (HASMC and HSC) treated with verticillin A at indicated doses for 24 h. (C) MTS assessment of leiomysarcoma (SKLMS1 and
LMS1) and MPNST (MPNST724 and S462) cell lines treated increasing concentrations of verticillin A for 24 h. (D) Analysis of colony
formation capability of S462, MPNST724, LMS1, and SKLMS1 upon treatment. (E) Cell cycle progression. *p<0.05, **p<0.01, ***p<0.001.
Citation: Zewdu A, Lopez G, Braggio D, Kenny C, Constantino D, et al. (2016) Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral
Nerve Sheath Tumor Growth via Induction of Apoptosis. Clin Exp Pharmacol 6: 221. doi:10.4172/2161-1459.1000221
Page 4 of 7
Clin Exp Pharmacol, an open access journal
ISSN: 2161-1459
Volume 6 • Issue 6 • 1000221
Figure 2: Verticillin A induces apoptosis in STS. (A) Cleaved caspase 3/7 activity as measured by time lapse microscopy. Representative images
are shown. (B) Annexin V/PI FACS analysis of apoptotic levels.
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Verticillin A reduces tumor growth in vivo
Next, the effects of verticillin A on STS tumor growth in vivo was
investigated via use of MPNST724 xenografts. MPNST724 cells
demonstrated higher tolerance to verticillin A (EC50=124.6 nM). It
was therefore predicted that any efficacy seen in the MPNST724
xenograft models would be amplified in the other STS lines, as based
on our EC50 data. MPNST724 xenografts demonstrated significant
tumor growth inhibition in the mice allocated to either verticillin A
treatment arms with the greatest effects observed with 0.5 mg/kg drug
(tumor volume=160.92 mm3, p ≤ 4.05E-06; tumor weight=0.2g, p ≤
6.77E-05) (Figure 3A-C); treatment with 0.25 mg/kg also significantly
reduced tumor volume (355.89 mm3, p ≤ 0.000147) by day 11
(Supplementary Figure 1).
Toxicity was observed in mice treated at the higher 0.5 mg/kg dose;
mice demonstrated reduced grooming tendencies and mild weight loss
(Figure 3D). Additionally, 2 mice were lost due to verticillin A-induced
mortality. Further toxicology studies are therefore needed to
understand the scope of these verticillin A-induced side effects.
Verticillin A also induced a nearly 40% decrease in the Ki67
proliferation marker expression in MPNST724 xenografts (Figure 3E).
To identify compound-induced apoptosis in vivo, we probed for the
cleaved caspase 3 apoptosis marker using IHC analysis. Verticillin A
treatment led to a 5.5-fold increase in cleaved caspase 3 expression in
MPNST724 tumors (Figure 3D). Taken together, the observed in vitro
selectivity and in vivo inhibitory effect of verticillin A supports further
evaluation of its potential as a useful anti-STS clinical agent (Figure 3).
Discussion
Verticillin A is a small molecule with demonstrated anticancer
activity via chromatin remodelling [10-12], although little is known on
the effects of verticillin A on normal cells. Our data demonstrate the
cytotoxic selectively of this agent toward STS cell lines compared to
normal cells. While verticillin A impairs growth effects on these
normal cells, their tolerance to verticillin A is greater than that of their
STS counterparts in comparing HASMC to LMS. Likewise, Liu et al.
demonstrated marked anticancer effects of verticillin A in colon
carcinoma cell lines and higher tolerance in normal human colon
epithelial cell (CCD-841) and donor T cells [11]. This selective
responsiveness of cancer cells to verticillin A suggests the potential
value of using these drugs in MPNST and LMS treatment.
Our data did not show cell cycle arrest in response to verticillin A;
instead, verticillin A treatment resulted in an anticancer effect
independent of cell cycle arrest. In contrast, verticillin A was shown to
induce G2 cell cycle arrest in SW620 colon cancer cells, though no
changes in cell cycle progression were observed in verticillin A-treated
HepG2 liver carcinoma cells [11]. Taken together, these observations
suggest that verticillin A may have various impacts on cell cycle
progression depending on cell type being investigated, implying
possible discrepancies in utilized pathways, differential metabolic
processes, and differences in genetic and proteomic expression.
Minor signs of toxicity and compound-mediated mortalities were
observed in the mice treated with the lower and higher doses of
verticillin A, respectively. Further investigation is therefore needed to
determine whether toxicity issues resolve following compound
withdrawal. Toxicity levels may potentially be mitigated through a
combinational therapeutic approach. In the exploration of
combination TRAIL/verticillin A therapy on high grade colon
carcinoma, Liu et al. were able to reduce the verticillin A dosage from
30-122 nM to 10 nM11, thereby successfully sensitizing tumor cells to
TRAIL treatment. Additionally, studies performed by our laboratory
have demonstrated an effect of broad-spectrum histone deacetylase
inhibitors (HDACis) on genetically complex STS [14,15], and
improved efficacy:toxicity ratio through HDAC isoform-specific
targeting [16]. Given the observed efficacy demonstrated by HDACis
and verticillin A as single agents, investigation of combined HDACis/
verticillin A therapeutic approaches may prove useful in the treatment
of patients with high grade STS.
Figure 3: Verticillin A inhibits MPNST724 growth in vivo. (A and
B.) Gross histology of tumors removed from mice treated with
either vehicle or 0.5 mg/kg verticillin A at day 11. (B) Tumor
burden by day 11 (p<0.0001). (C) Mouse body weight. (D) IHC
analysis of proliferation (Ki67, p=0.015) and apoptosis (cleaved
caspase 3, p=0.042) upon treatment with 0.5 mg/kg verticillin A
treatment.
The study of the anti-tumor effects of natural compounds is a
decades-long effort to identify more efficacious treatment strategies;
between 1981 and 2010, 48.6% of all new drugs introduced during this
time were marine-, microorganism-, or plant-derived, roughly 65% of
which are anticancer compounds [17,18]. These discoveries thereby
support the continued investigation of new and understudied natural
compounds in hopes of identifying novel compounds with selective
anticancer potency.
Many natural compounds, such as romidepsin [19], have been
shown to display growth inhibitory capacities in STS [20,21]. Given the
success seen in the in vitro investigation of other bioactive compounds,
investigation of the natural product verticillin A in STS was warranted.
Our exploration of verticillin A suggests the possible value of this agent
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in patient care; however, the results are still preliminary and will
require further evaluation for the potential treatment of patients with
MPNST and LMS.
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